On July 16, 2020 Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that the company will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m. ET to report its second quarter 2020 financial results and other business highlights (Press release, Agios Pharmaceuticals, JUL 16, 2020, https://investor.agios.com/news-releases/news-release-details/agios-webcast-conference-call-second-quarter-2020-financial [SID1234561940]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 2955575. The webcast will be archived and made available for replay on the company’s website beginning approximately two hours after the event.

On July 16, 2020 Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol Myers Squibb") reported the expiration and final results of its offers to exchange (the "Registered Exchange Offers") any and all of its outstanding (i) $19,000,000,000 aggregate principal amount of senior unsecured notes previously issued on May 16, 2019 ("May Notes") pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), and (ii) $18,545,623,000 aggregate principal amount of its outstanding senior unsecured notes previously issued on November 22, 2019 (the "November Notes" and, together with the May Notes, the "Original Notes") pursuant to an exemption from the registration requirements of the Securities Act, for an equal principal amount of new notes in a transaction registered under the Securities Act (the "Registered Notes") (Press release, Bristol-Myers Squibb, JUL 16, 2020, View Source [SID1234561939]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Registered Exchange Offer expired at 5:00 p.m., New York City time, on July 15, 2020 (the "Expiration Date"). As of the Expiration Date, the aggregate principal amounts of Original Notes set forth in the table below had been validly tendered and not validly withdrawn. Bristol Myers Squibb has accepted for exchange all such tendered Original Notes in the Registered Exchange Offers.

Title of Series of Original Notes

Amount
Outstanding at
Commencement

Amount
Tendered as of the
Expiration Date

Percentage

2.875% Senior Notes due 2020

$1,243,777,000

$1,186,279,000

95.38%

3.950% Senior Notes due 2020

$436,313,000

$425,282,000

97.47%

Senior Floating Rate Notes due 2020

$750,000,000

$712,942,000

95.06%

2.875% Senior Notes due 2021

$434,815,000

$406,758,000

93.55%

2.250% Senior Notes due 2021

$464,576,000

$452,743,000

97.45%

2.550% Senior Notes due 2021

$1,000,000,000

$963,195,000

96.32%

3.250% Senior Notes due 2022

$861,709,000

$855,002,000

99.22%

3.550% Senior Notes due 2022

$891,870,000

$890,930,000

99.89%

Senior Floating Rate Notes due 2022

$500,000,000

$485,088,000

97.02%

2.600% Senior Notes due 2022

$1,500,000,000

$1,488,572,000

99.24%

2.750% Senior Notes due 2023

$697,660,000

$688,878,000

98.74%

3.250% Senior Notes due 2023

$932,101,000

$924,851,000

99.22%

4.000% Senior Notes due 2023

$636,086,000

$624,976,000

98.25%

3.625% Senior Notes due 2024

$882,510,000

$882,403,000

99.99%

2.900% Senior Notes due 2024

$3,250,000,000

$3,208,481,000

98.72%

3.875% Senior Notes due 2025

$2,379,532,000

$2,368,581,000

99.54%

3.200% Senior Notes due 2026

$2,250,000,000

$2,243,559,000

99.71%

3.450% Senior Notes due 2027

$961,528,000

$960,491,000

99.89%

3.900% Senior Notes due 2028

$1,456,162,000

$1,450,092,000

99.58%

3.400% Senior Notes due 2029

$4,000,000,000

$3,968,935,000

99.22%

4.125% Senior Notes due 2039

$2,000,000,000

$1,995,600,000

99.78%

5.700% Senior Notes due 2040

$245,785,000

$245,637,000

99.94%

5.250% Senior Notes due 2043

$391,925,000

$388,625,000

99.16%

4.625% Senior Notes due 2044

$976,477,000

$975,977,000

99.95%

5.000% Senior Notes due 2045

$1,959,524,000

$1,958,923,000

99.97%

4.350% Senior Notes due 2047

$1,236,433,000

$1,236,433,000

100.00%

4.550% Senior Notes due 2048

$1,456,840,000

$1,447,340,000

99.35%

4.250% Senior Notes due 2049

$3,750,000,000

$3,749,500,000

99.99%

Total

$37,545,623,000

$37,186,073,000

99.04%

Upon the settlement of the Registered Exchange Offers, holders of Original Notes who validly tendered and did not validly withdraw such notes prior to the Expiration Date will receive a like principal amount of Registered Notes of the applicable series. Bristol Myers Squibb expects that such settlement will occur on or about July 17, 2020.

The terms of the Registered Notes to be issued in the Registered Exchange Offers are substantially identical to the terms of the corresponding series of Original Notes, except that the issuance of the Registered Notes will be registered under the Securities Act and the transfer restrictions, registration rights and additional interest provisions applicable to the Original Notes will not apply to the Registered Notes. Bristol Myers Squibb will issue the Registered Notes under the same indentures that govern the applicable series of Original Notes. The Registered Exchange Offers do not represent a new financing transaction.

A Registration Statement on Form S-4 (File No. 333-238533) (the "Registration Statement") relating to the Registered Exchange Offers was filed with the Securities and Exchange Commission on May 20, 2020 and was declared effective on June 15, 2020. The Registered Exchange Offers were made pursuant to the terms and subject to the conditions set forth in a prospectus dated June 16, 2020 (as the same may be amended or supplemented, the "Prospectus"), which has been filed with the Securities and Exchange Commission and forms a part of the Registration Statement.

This press release is not an offer to sell or exchange or a solicitation of an offer to buy or exchange any of the securities described herein.

On July 16, 2020 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") reported the appointment of Dr. Joyson Karakunnel as Executive Vice President and Chief Medical Officer (CMO) (Press release, Innate Pharma, JUL 16, 2020, View Source [SID1234561938]). Dr. Pierre Dodion, CMO since 2014, is retiring from this position.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Karakunnel comes to the Company with deep experience in immuno-oncology, and a proven track record in drug development. As CMO, he will be responsible for advancing Innate’s clinical pipeline and will lead a global team focused on clinical strategy, patient safety, regulatory and medical affairs.

Most recently, Dr. Karakunnel served as CMO and Senior Vice President at Tizona Therapeutics, where he led the development of the company’s biotherapeutics pipeline. Prior to Tizona, he held positions with Arcus Biosciences and AstraZeneca/MedImmune; his collective responsibilities included leading clinical development activities, drug safety and regulatory affairs. In addition, he serves as a medical advisor at the Parker Institute for Cancer Immunotherapy.

"We are pleased to welcome Dr. Joyson Karakunnel as our new Chief Medical Officer. As an experienced medical oncologist, Joyson brings in-depth immunology, oncology and hematology expertise, which will help further strengthen and accelerate the delivery of new medicines to patients," said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. "We are also grateful for Pierre’s invaluable contributions. During his six years at Innate, he drove the advancement of several key assets to late-stage clinical development, which will have a lasting impact on the Company."

Dr. Dodion joined Innate in 2014 and has been instrumental in the Company’s clinical strategy, successfully advancing key oncology programs to late-stage status. He has led the clinical development of several therapeutic programs, including monalizumab, a potentially first-in-class immune checkpoint inhibitor, and lacutamab, a first-in-class antibody designed for the treatment of advanced T-cell lymphomas. Dr. Dodion will transition to a consulting role with Innate following his retirement.

Dr. Joyson Karakunnel

Adding to his track record in oncology and hematology drug development, Dr. Karakunnel also served as a clinical trial investigator at the National Cancer Institute and a team leader for the hematologic group at Walter Reed National Military Medical Center. In addition, he was an associate professor at the Uniformed Services University of the Health Sciences and a medical reviewer at the U.S. Food and Drug Administration.

"I’m proud to join Innate at this exciting juncture with several molecules moving into late-stage development, new molecules moving into the clinic and novel indications being pursued in oncology as well as for COVID-19," said Joyson Karakunnel, Chief Medical Officer of Innate Pharma. "This is clearly a company with a robust pipeline and unique focus on the innate immune system, which complements the work I’ve done in both the academic and industry settings. I look forward to further advancing the innovative science with the talented scientists and clinicians at the Company."

Dr. Karakunnel completed fellowships in hematology and oncology at the National Cancer Institute and completed his internal medicine residency at the University of Medicine and Dentistry of New Jersey, where he was chief resident. He obtained his MD from Annamalai University in India, and also holds a MSc in pharmacology from the University of Maryland.

Dr. Karakunnel will be based in Innate’s Rockville, Maryland office.

On July 16, 2020 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of Sample to Insight molecular diagnostics and sample preparation technologies, reported that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN (Press release, Qiagen, JUL 16, 2020, View Source [SID1234561937]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The amendment provides for an increase from the original offer price of €39.00 to a new price of €43.00 per QIAGEN share in cash, which represents a premium of approximately 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the acquisition agreement and Thermo Fisher’s intention to commence the offer. The amendment also provides for a reduction of the minimum acceptance threshold from 75% to 66.67% of QIAGEN’s issued and outstanding ordinary share capital at the end of the acceptance period on August 10, 2020, as well as a USD 95 million expense reimbursement to Thermo Fisher if the minimum acceptance threshold is not met.

The members of QIAGEN’s Supervisory Board and Managing Board have reaffirmed their unanimous support for the offer and their unanimous recommendation that all QIAGEN shareholders accept and tender all of their QIAGEN shares in the offer prior to the end of the acceptance period, which has now been extended to August 10, 2020. Each of the members of the Supervisory Board and Managing Board has tendered or will tender all of their QIAGEN shares in the offer.

Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific, said, "Industry dynamics have changed considerably in the past few months, creating tailwinds and headwinds for our businesses. Both of our companies are playing important roles in helping customers to battle the COVID-19 pandemic. After careful consideration, we’ve decided to increase our offer for QIAGEN to reflect the fair

value of the business given the current environment. We remain confident that this transaction will create shareholder value and, importantly, provide meaningful benefits to our customers and society by combining our capabilities to combat infectious diseases and other healthcare issues. We continue to look forward to completing the transaction in the first half of 2021."

"After carefully considering the updated offer by Thermo Fisher, QIAGEN’s Supervisory Board and Managing Board both unanimously recommend that shareholders accept this offer given that it reflects the improvements in our business performance and future prospects as a result of the coronavirus pandemic," said Thierry Bernard, chief executive officer of QIAGEN N.V. "The rationale for this strategic step is stronger than ever, especially as the value of molecular testing becomes ever more evident. This combination is designed to enable QIAGEN employees and our portfolio of Sample to Insight solutions to have an even greater impact on society while also delivering significant cash value to our shareholders. We look forward to working closely with Thermo Fisher to successfully complete the transaction."

QIAGEN shareholders who have already effectively accepted the offer by tendering their shares are not required to take further action in order to receive the increased offer price in accordance with the terms of the offer. Thermo Fisher’s tender offer statement on Schedule TO, including the offer document that is an exhibit thereto, and QIAGEN’s solicitation/recommendation statement on Schedule 14D-9 will be amended to reflect the revised terms of the transaction. The acceptance period is now scheduled to expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on August 10, 2020.

Advisors

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are serving as financial advisors to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel. For QIAGEN, Goldman Sachs International is serving as lead financial advisor and Barclays Bank PLC is serving as financial advisor, while De Brauw Blackstone Westbroek NV, Linklaters LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C. are serving as legal counsel.

On July 16, 2020 INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, reported the pricing of its underwritten public offering of an aggregate of 2,173,914 shares of its common stock at a public offering price of $10.00 per share (Press release, INmune Bio, JUL 16, 2020, View Source [SID1234561936]). In addition, INmune has granted the underwriters an over-allotment option, exercisable for 45 days from today to purchase up to an additional 326,086 shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about July 20, 2020, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The gross proceeds to INmune from this offering are expected to be approximately $21.7 million, before deducting underwriting discounts and commissions and other offering expenses payable by INmune but excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Net proceeds are estimated to be $20 million. INmune intends to use the net proceeds from the offering for general corporate purposes, including to support research and development, including clinical trials.

BTIG, LLC is acting as sole book-running manager of the offering, and National Securities Corporation is acting as a co-manager.

The offering is being made pursuant to the shelf registration statement on Form S-3 (File No. 333-237368) that was filed with the Securities and Exchange Commission (the "SEC") on March 24, 2020 and became effective on April 2, 2020. The offering is being made only by means of written prospectuses and prospectus supplements that form part of the registration statements. Preliminary prospectus supplements and accompanying prospectuses relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. The final prospectus supplements and accompanying prospectuses for each offering will be filed with the SEC. When available, copies of the final prospectus supplements and accompanying prospectuses for each offering may be obtained for free from BTIG, LLC, Attention: Equity Capital Markets, 65 East 55th Street, New York, NY 10022, by telephone at (212) 593-7555 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.